#USA #Jersey City #Public Offering #WallachBeth Capital #Tenon Medical

WallachBeth Capital Announces Tenon Medical's Securities Offering

On June 30, 2026, WallachBeth Capital LLC revealed the pricing details for Tenon Medical, Inc.'s recent public offering, which aims to raise approximately $4.2 million. Tenon Medical, specializing in innovative medical devices for sacro-pelvic disorders, has structured this offering to involve a combination of common stock and warrants, designed to strengthen its financial position and operational capabilities.

Offering Details

The offering includes up to 11,052,631 shares of common stock at a price of $0.38 per share. This figure also encompasses pre-funded warrants, allowing investors additional flexibility in their purchase options. Accompanying these shares are common stock purchase warrants that grant holders the right to acquire up to 13,263,159 shares, enhancing the attractiveness of the offering for potential investors.

The net proceeds from this public offering are earmarked for several strategic initiatives. Tenon Medical will utilize the funds primarily for the repayment of existing convertible notes, which enhances their financial stability. Additionally, a portion of the proceeds is allocated for expanding their commercial footprint, which is crucial for the wider distribution and acceptance of their medical products.

This initiative includes essential training for clinicians on existing procedures and hiring more direct sales representatives to bolster their sales efforts. The company is also committed to advancing its external distribution network, ensuring that their innovative solutions reach a broader audience more effectively.

Continuing Research and Development

Tenon Medical's focus on continuing clinical research studies is also a key aspect of their strategy, as these efforts are vital for supporting reimbursement and coverage. This not only helps in the refinement of their current offerings but also supports future launches and innovation in their product pipeline. Moreover, part of the funds will also go towards increasing inventory and instrumentation capacities, ensuring that they are well-prepared to meet future demand.

The offering comes with the responsibility of providing transparent communication to investors, and WallachBeth Capital serves as the sole placement agent, ensuring compliance with securities regulations. The firm’s experience in capital markets aids Tenon Medical in navigating this complex process effectively, making it a trusted partner in these endeavors.

Legal and Compliance Considerations

Legal representation in this offering includes Sichenzia Ross Ference Carmel LLP for Tenon Medical and Sheppard, Mullin, Richter and Hampton LLP for WallachBeth Capital, ensuring all transactions comply with the relevant securities laws. The offering will be conducted in adherence to the Securities and Exchange Commission (SEC) regulations, promoting a secure investment environment for all participants.

Investors are advised that the common warrants are expected to be immediately exercisable, thereby allowing for rapid engagement with the company’s growth trajectory. This offering stands as an opportunity for investment not only in securities but also in support of innovation and improvements in medical care, particularly for those suffering from sacro-pelvic disorders.

Conclusion

As Tenon Medical embarks on this crucial period of development, the $4.2 million public offering serves as a foundation for furthering their mission to transform patient care. With strategic investments in sales, marketing, and research, Tenon Medical appears well-positioned to advance its objectives in the competitive medical device industry. Prospective investors can look forward to additional disclosures as the company moves forward, providing insights into their progress and future initiatives.